Hemogenyx Pharmaceuticals Plc (LON: HEMO)

Market Cap	16.10M
Revenue (ttm)	n/a
Net Income (ttm)	-5.18M
Shares Out	1.34B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	102,869,447
Open	1.724
Previous Close	1.525
Day's Range	0.878 - 1.950
52-Week Range	0.878 - 7.130
Beta	3.15
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 27, 2024

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company’s lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hema...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 17
• Stock Exchange: London Stock Exchange
• Ticker Symbol: HEMO